Reviewer’s report

Title: Phase II Study of Weekly Paclitaxel and Capecitabine in Patients with Metastatic or Recurrent Esophageal Squamous Cell Carcinoma

Version: 2 Date: 17 June 2011

Reviewer: Hugo Ford

Reviewer’s report:

I feel that the decision to amend the trial design partway through is still not well justified, and this remains a significant flaw in the report. The statistical design is as a result fundamentally flawed.

However on balance I would recommend that it be published, but the flawed design reduces the strength of the data

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

My declaration is unchanged from the initial review